Please login to the form below

ThromboGenics

This page shows the latest ThromboGenics news and features for those working in and with pharma, biotech and healthcare.

NICE backs Novartis/ ThromboGenics’ eye drug

It is also good news for the drug's original developers ThromboGenics, which sold non-US rights for Jetrea to Novartis in 2012 in a deal worth up to 375m, and ... progressive disease much earlier and as soon as patients start experiencing symptoms

Latest news

NICE backs Novartis' Jetrea in rare eye condition

Once launched, Jetrea will be marketed by Novartis' eye division Alcon, which purchased non-US rights to the drug from Belgian pharma company ThromboGenics in March 2012. ... ThromboGenics retains the rights to commercialise the drug in the US, where it
Alcon wins initial NICE backing for Jetrea in rare eye condition

It purchased the rights to commercialise Jetrea outside the US from its developers ThromboGenics in 2012 as part of a deal potentially worth up to 375m.
Novartis, ThromboGenics' eye drug Jetrea gets green light in EU

The availability of the drug is a major boon for VMA patients, who until now have only had surgery as a treatment option, according to ThromboGenics. ... Jetrea was approved for symptomatic VMA last year in the US, where ThromboGenics has retained
Novartis' eye drug Jetrea recommended for EU approval

Novartis' Alcon division acquired commercialisation rights to Jetrea from its discoverer, the Belgium-based biopharmaceutical company ThromboGenics, in a 375m deal last March.
Amakem raises €18m for glaucoma treatment

Chris Buyse (Life Sciences Research Partners and CFO at Thrombogenics) who has been the company's chairman during its successful first phase will step down and Michael Palfreyman will take his

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest appointments

ThromboGenics bolsters leadership team

Appoints Susan Schneider as CMO and Vinciane Vangeersdaele as CCO. ThromboGenics has strengthened its senior leadership team with the appointment of Susan Schneider, who joins the Belgian biotech as its chief ... Patrik De Haes, chief executive officer,
ThromoboGenics appoints Thomas Clay as chairman of the board

He moves from his previous position as non-executive director. Belgium-based biotech ThromboGenics has appointed non-executive director Thomas Clay as its new chairman of the board and succeeds Staf ... Clay has been a non-executive director of

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Account Manager – Healthcare advertising: Salary TBC

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer: Competitive salary plus benefits

Events Executive: DOE

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Director – UK Office: Excellent salary and benefits

Client Services Director- Flexible Working: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...